Baylor Scott & White Health | Strategic Alliance Partners

June 30, 2021

David P. Mason, MD, discusses new neoadjuvant and adjuvant developments in the treatment of patients with non–small cell lung cancer, as well as what those data mean from a surgical perspective.

June 25, 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after previous neoadjuvant chemoradiotherapy.

June 15, 2021

June 05, 2021

Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.

May 24, 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

May 22, 2021

YoungNa Lee-Kim, MD, shares advice on how to advance as an oncology fellow.

May 15, 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

November 11, 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

October 07, 2020

Ronan J. Kelly, MD, MBA, explains how the results of the KEYNOTE-407 trial have positioned pembrolizumab plus chemotherapy as the frontline standard of care in this setting.

August 18, 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

April 15, 2020

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

May 20, 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

May 15, 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

May 14, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

May 07, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

May 03, 2019

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

May 02, 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.

May 02, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).

May 01, 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.

May 01, 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.